Education
About Us
Working with TipRanks
Follow Us
CNS Pharmaceuticals (CNSP)
NASDAQ:CNSP
Total Valuation
CNS Pharmaceuticals has a market cap or net worth of $5.13M. The enterprise value is $163.40B.
Market Cap$5.13M
Enterprise Value$163.40B
Share Statistics
CNS Pharmaceuticals has 5,461,951 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,461,951
Owned by Insiders10.50%
Owned by Institutions0.21%
Financial Efficiency
CNS Pharmaceuticals’s return on equity (ROE) is -2.41 and return on invested capital (ROIC) is -229.17%.
Return on Equity (ROE)-2.41
Return on Assets (ROA)-1.71
Return on Invested Capital (ROIC)-229.17%
Return on Capital Employed (ROCE)-2.41
Revenue Per Employee0.00
Profits Per Employee-3.71M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CNS Pharmaceuticals is -1.55. CNS Pharmaceuticals’s PEG ratio is 312.58.
PE Ratio-1.55
PS Ratio0.00
PB Ratio20.09K
Price to Fair Value3.73
Price to FCF-15.47K
Price to Operating Cash Flow-15.48K
PEG Ratio312.58
Income Statement
In the last 12 months, CNS Pharmaceuticals had revenue of 0.00 and earned -14.86M in profits. Earnings per share was -38.87.
Revenue0.00
Gross Profit-3.31K
Operating Income-14.90M
Pretax Income-14.86M
Net Income-14.86M
EBITDA-14.90M
Earnings Per Share (EPS)-38.87
Cash Flow
In the last 12 months, operating cash flow was -17.16M and capital expenditures -4.19K, giving a free cash flow of -17.17M billion.
Operating Cash Flow-17.16M
Free Cash Flow-17.17M
Free Cash Flow per Share-3.14
Dividends & Yields
CNS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.29
52-Week Price Change-98.49%
50-Day Moving Average1.02
200-Day Moving Average3.86
Relative Strength Index (RSI)48.85
Average Volume (3m)225.04K
Important Dates
CNS Pharmaceuticals upcoming earnings date is Aug 18, 2025, After Close (Confirmed).
Last Earnings DateMay 16, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
CNS Pharmaceuticals as a current ratio of 3.43, with Debt / Equity ratio of 5.04%
Current Ratio3.43
Quick Ratio3.43
Debt to Market Cap0.01
Net Debt to EBITDA0.41
Interest Coverage Ratio-924.50
Taxes
In the past 12 months, CNS Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CNS Pharmaceuticals EV to EBITDA ratio is -1.13, with an EV/FCF ratio of -0.99.
EV to Sales0.00
EV to EBITDA-1.13
EV to Free Cash Flow-0.99
EV to Operating Cash Flow-0.99
Balance Sheet
CNS Pharmaceuticals has $13.05M in cash and marketable securities with $210.67K in debt, giving a net cash position of -$12.84M billion.
Cash & Marketable Securities$13.05M
Total Debt$210.67K
Net Cash-$12.84M
Net Cash Per Share-$2.35
Tangible Book Value Per Share$1.62
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CNS Pharmaceuticals is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.00
Price Target Upside644.68% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast90.33%